Melissa FULLWOOD   
    Main Page   Publications              
a filler
  Melissa FULLWOOD  
  Lab Location: Cancer Science Institute of Singapore, 14 Medical Drive, #12-01 Centre for Translational Medicine, MD6 Singapore 117599

a a a
a a a
  Key Publications  

The ENCODE Project Consortium, An Integrated Encyclopedia of DNA Elements in the Human Genome,
Nature. 2012.

Li, G., et al.,
Extensive Promoter-centered Interactions provide Higher-order Framework for Transcription Regulation in Human Cells,
Cell. 2012.

Fullwood, M.J., Han, Y.Y., Wei, C.L., Ruan, X., Ruan, Y. Chromatin Interaction Analysis using Paired-End Tag Sequencing, Current Protocols in Molecular Biology. 2010.

Li, G., Fullwood, M.J., Han X., et al.
ChIA-PET Tool for Comprehensive Chromatin Interaction Analysis with Paired-End Tag Sequencing,
Genome Biology. 2010.

Fullwood, M.J., et al.
The Oestrogen Receptor a-mediated Human Chromatin Interactome,
Nature. 2009.

Fullwood, M.J., Wei, C.L., Liu, E. T. and Ruan, Y.
Ultra-High-Throughtput Sequencing of Paired-End Tags (PET) for Transcriptome and Genome Analyses,
Genome Res. 2009.




a a a
  Melissa FULLWOOD

Melissa Fullwood completed her B.Sc. (Honours) in Biological Sciences at Stanford University and received her Ph.D. from the NUS Graduate School for Integrative Sciences and Engineering (NGS) at the Genome Institute of Singapore. She was a Lee Kuan Yew Post-Doctoral Fellow at Duke-NUS. She became an Assistant Professor at Yale-NUS and a Special Fellow at the Cancer Science Institute in 2012. Following the award of a National Research Foundation Fellowship in 2013, she became a Junior Principal Investigator at the Cancer Science Institute. She was a recipient of the Agency for Science, Technology and Research (A*STAR) National Science Scholarships, a recipient of the L'Oreal-UNESCO for Women in Science National Fellowship Singapore in 2009, and the international winner of the GE and Science prize in 2010. Melissa is a co-inventor on two patents on chromatin interaction analysis with paired-end tag sequencing (ChIA-PET).


Cancer Epigenomics Lab


Cancer genome sequencing has revealed that many factors associated with epigenetic processes are mutated in cancers, and epigenetic processes have been targeted by specific drugs. The Cancer Epigenomics Laboratory examines epigenomic features of the cancer genome, such as chromatin interactions, transcription factors, histone modifications and long non-coding RNAs. This work is expected to have translational applications in terms of annotations for personal and clinical sequencing and development of clinical biomarkers. One of the mechanisms by which the non-coding "dark matter" of the human genome could be functional is by long-range chromatin interactions with target genes. Chromatin interactions are regions of the genome that are far apart in the linear genome sequence but come together in close 3-dimensional spatial proximity, may constitute common mechanisms for gene regulation. The lab currently focuses on using ChIP sequencing, RNA sequencing, as well as ChIA-PET for genome-wide elucidation of chromatin interactions, on cancer models to investigate detailed epigenomic profiles, allowing for new insights into possible cancer-associated biomarkers and cancer therapies. In addition, the lab is interested in continuing to develop and refine new genomic technologies to better understand chromatin and transcription. More details about the lab can be found at

Figure Legend: Translational implications of cancer epigenomics. Inset: Chromatin Interaction Analysis with Paired-End Tag Sequencing (ChIA-PET), a genome-wide method for elucidating chromatin interactions.